Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Hangzhou Tigermed Consulting Co., Ltd
  6. Summary
    300347   CNE100001KV8

HANGZHOU TIGERMED CONSULTING CO., LTD

(300347)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
172.9 172.18 174.74 167 162.6 Last
5281795 4421514 5450455 7349576 7060620 Volume
-1.46% -0.42% +1.49% -4.43% -2.63% Change
Estimated financial data (e)
Sales 2021 4 076 M 629 M 629 M
Net income 2021 1 814 M 280 M 280 M
Net cash position 2021 12 194 M 1 881 M 1 881 M
P/E ratio 2021 77,2x
Yield 2021 0,24%
Sales 2022 5 460 M 842 M 842 M
Net income 2022 2 126 M 328 M 328 M
Net cash position 2022 13 355 M 2 061 M 2 061 M
P/E ratio 2022 66,1x
Yield 2022 0,29%
Capitalization 139 B 21 437 M 21 439 M
EV / Sales 2021 31,1x
EV / Sales 2022 23,0x
Nbr of Employees -
Free-Float 100,0%
More Financials
Company
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). 
More about the company
Ratings of Hangzhou Tigermed Consulting Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about HANGZHOU TIGERMED CONSULTING CO., LTD
07/23HANGZHOU TIGERMED CONSULTING : Shareholders to Vote Aug. 9 on $3 Billion Healthc..
MT
07/21Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes
CI
07/13HANGZHOU TIGERMED CONSULTING : Hanzhou Tigermed Setting Up $3 Billion Healthcare..
MT
07/13Adlai Nortye Biopharma Co., Ltd. announced that it has received $100 million ..
CI
07/12Hangzhou Tigermed Consulting Co., Ltd Enters into Partnership Agreement with ..
CI
07/06Chinese Pharma Stocks Drop on Proposed New Rules for Oncology Drug Trials
DJ
07/06China stocks end lower as healthcare, tech firms tumble
RE
07/06China stocks fall on healthcare slump; Hong Kong down
RE
06/13HANGZHOU TIGERMED CONSULTING : Tigermed Consulting Signs Deal with Other Parties..
MT
06/09Hipower Pharmaceutical announced that it has received $10.95 million in fundi..
CI
05/26Hangzhou Tigermed Consulting Co., Ltd Announces 2020 Final Distribution Plan ..
CI
05/24Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year 2..
CI
04/30HANGZHOU TIGERMED CONSULTING : 2020 Tigermed Sustainability Report And Environme..
PU
04/29HANGZHOU TIGERMED CONSULTING : Q1 Profit, Revenue Surge
MT
04/28Hangzhou Tigermed Consulting Co.,Ltd Reports Earnings Results for the First Q..
CI
More news
News in other languages on HANGZHOU TIGERMED CONSULTING CO., LTD
07/06UPDATE/MÄRKTE ASIEN/Richtungswechsel in Sydney nach RBA-Beschlüssen
More news
Chart HANGZHOU TIGERMED CONSULTING CO., LTD
Duration : Period :
Hangzhou Tigermed Consulting Co., Ltd Technical Analysis Chart | 300347 | CNE100001KV8 | MarketScreener
Technical analysis trends HANGZHOU TIGERMED CONSULTING CO., LTD
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 162,60 CNY
Average target price 186,21 CNY
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Xiao Ping Ye Chairman & General Manager
Jun Gao Chief Financial Officer & Senior Vice President
Xiao Li Shi Chairman-Supervisory Board
Bi Yun Zheng Independent Director
Su Zeng Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HANGZHOU TIGERMED CONSULTING CO., LTD0.61%25 482
MODERNA, INC.233.90%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.39.02%47 022
CELLTRION, INC.-25.21%32 170
SEAGEN INC.-16.87%28 525